Immunomodulatory antibodies for therapy of cancer
HAMDAN MEDICAL JOURNAL · 2014
DOI: 10.7707/hmj.404 ↗Kurz gefasst
Fachartikel in der Zeitschrift HAMDAN MEDICAL JOURNAL, 2014. Verfasst von Ingegerd Hellstrom und 2 weiteren Autor:innen.
Abstract (Originalsprache)
It has been known for many years that immunological mechanisms play a key role in cancers, including those which are most common in humans. However, for several decades, the benefit of active immunotherapy was modest. This situation is now rapidly changing. In particular, systemic administration of immunomodulatory monoclonal antibodies (mAbs) has demonstrated clinical efficacy, including complete remission in several patients treated at tolerable toxicity for melanoma or other particular types of tumours.6,7 These findings are remarkable but much remains to be learned.
Zitieren
APA
Hellstrom, I., Dai, M., & Hellstrom, K. E. (2014). Immunomodulatory antibodies for therapy of cancer. HAMDAN MEDICAL JOURNAL. https://doi.org/10.7707/hmj.404
Vancouver
Hellstrom I, Dai M, Hellstrom KE. Immunomodulatory antibodies for therapy of cancer. HAMDAN MEDICAL JOURNAL. 2014. doi:10.7707/hmj.404
BibTeX
@article{Hellstrom2014,
author = {Hellstrom, Ingegerd and Dai, Min and Hellstrom, Karl Erik},
title = {Immunomodulatory antibodies for therapy of cancer},
journal = {HAMDAN MEDICAL JOURNAL},
year = {2014},
doi = {10.7707/hmj.404}
}
EUVIMED